| Drug Name |
Interferon alfacon-1 |
| Drug ID |
BADD_D01168 |
| Description |
Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional amino acid changes were made to facilitate the molecular construction, and a corresponding synthetic DNA sequence was constructed using chemical synthesis methodology. Interferon alfacon-1 differs from interferon alfa-2b at 20/166 amino acids (88% homology), and comparison with interferon-beta shows identity at over 30% of the amino acid positions. Interferon alfacon-1 is produced in Escherichia coli (E. coli) cells that have been genetically altered by insertion of a synthetically constructed sequence that codes for Interferon alfacon-1. Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns. This protein has a molecular weight of 19,434 daltons. |
| Indications and Usage |
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma |
| Marketing Status |
approved; investigational |
| ATC Code |
L03AB09 |
| DrugBank ID |
DB00069
|
| KEGG ID |
D02744
|
| MeSH ID |
C050739
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0GA0A
|
| NDC Product Code |
Not Available |
| UNII |
56588OP40D
|
| Synonyms |
interferon alfacon-1 | IFN-alpha Con 1 | consensus IFN-alpha | interferon-alpha Con(1) | rIFN-con-1 | recombinant consensus interferon alpha | CIFN (interferon) | Infergen | Inferax |
